TheProfitWatch

TSHA - Taysha Gene Therapies, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
5.18 0.15 (2.9%) --- 0.0 (0.0%) 0.0 (0.01%) 0.13 (2.51%) 0.0 (0.0%) -0.02 (-0.33%) -0.02 (-0.33%)

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Closed

Earnings & Ratios

Basic EPS:
-0.09
Diluted EPS:
-0.09
Basic P/E:
-59.2222
Diluted P/E:
-59.2222
RSI(14) 1m:
100.0
VWAP:
5.33
RVol:

Events

Period Kind Movement Occurred At

Related News